WO2021221485A1 - 이중 돌연변이를 가지는 인간 인터페론-베타 변이체 및 인간 인터페론-베타 변이체의 안정성을 향상시키는 방법 - Google Patents
이중 돌연변이를 가지는 인간 인터페론-베타 변이체 및 인간 인터페론-베타 변이체의 안정성을 향상시키는 방법 Download PDFInfo
- Publication number
- WO2021221485A1 WO2021221485A1 PCT/KR2021/005487 KR2021005487W WO2021221485A1 WO 2021221485 A1 WO2021221485 A1 WO 2021221485A1 KR 2021005487 W KR2021005487 W KR 2021005487W WO 2021221485 A1 WO2021221485 A1 WO 2021221485A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- beta
- human interferon
- acid
- amino acid
- interferon
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- interferon-beta has antiviral activity, cell growth inhibition or anti-growth activity, lymphocyte cytotoxicity enhancing activity, immunomodulatory activity, target cell differentiation induction or inhibitory activity, macrophage activation activity, cytokine production increasing activity , cancer, autoimmune disorders and viral infections, HIV-related diseases, hepatitis C, rheumatoid arthritis, etc. It has been reported to have therapeutic effects.
- the present inventors repeated intensive research to develop a method for improving the stability of the human interferon-beta variant R27T variant, more specifically tablet stability, storage stability, and freeze/thaw stability.
- the R27T variant By substituting serine for cysteine at the 17th amino acid (C17S), it was discovered that this object could be achieved and the present invention was completed.
- an object of the present invention is to have the pharmacological effect of natural human interferon-beta, and to administer an effective amount of a composition comprising the human interferon-beta mutant to an individual in need thereof. It provides a method of treating a disease selected from the group consisting of multiple sclerosis, cancer, autoimmune disorders, viral infections, HIV-related diseases, and hepatitis C, including those.
- the present invention provides an animal cell transformed with the expression vector and a method for producing a human interferon-beta mutant by culturing the animal cell.
- Human interferon-beta contained in the pharmaceutical composition of the present invention has been mainly used as a treatment for multiple sclerosis, but there are reports that it can be used for the treatment of cancer, autoimmune disorders, viral infections, HIV-related diseases, hepatitis C, etc. and its pharmacological effect has been continuously reported.
- composition of the present invention may be administered orally or through other routes including transdermal, subcutaneous, intravenous or intramuscular.
- cysteine which is the 17th amino acid of the human interferon-beta R27T mutant
- C17S serine
- arginine which is the 27th amino acid
- cysteine which is the 17th amino acid
- a host cell is transformed with a vector containing a polynucleotide encoding a protein. After conversion, it can be carried out by a method of culturing it in a medium.
- the polynucleotide encoding the human interferon-beta variant encodes a protein in which arginine, which is the 27th amino acid of wild-type human interferon-beta of SEQ ID NO: 1, is substituted with threonine, and cysteine, which is the 17th amino acid, is substituted with serine.
- Any polynucleotide sequence may be included without limitation.
- the polynucleotide is in the coding region within a range that does not change the amino acid sequence of the protein due to the degeneracy of the codon or in consideration of the codon preferred in the organism in which the protein is to be expressed. Various modifications may be made.
- the purification stability may be characterized as a reduction in protein aggregation and degradation during protein concentration and buffer exchange.
- a protein or polypeptide may undergo aggregation or degradation in the concentration and buffer exchange steps performed during/or after the purification process. Protein denaturation during buffer exchange may be reduced.
- Ultrafiltration for protein concentration is a separation method in which water pressure is used to force molecules and solvents across a membrane made of pores known as the particle size and also the cut-off size. Since molecules with a higher molecular weight do not pass through the membrane, only molecules with a molecular weight less than the barrier value of the membrane can pass through the membrane and form a so-called preservative. Thereby, the molecules present in the holding solution are concentrated as the solvent flows across the membrane. Ultrafiltration may be used for protein concentration or buffer exchange, or may be used to formulate a protein of interest into a desired solution or a desired buffer.
- concentration of a solution or composition comprising a protein of interest may be performed by tangential flow filtration (TFF).
- TFF tangential flow filtration
- concentration of the composition comprising the polypeptide of interest may be performed by use of a centrifugation device.
- the protein of interest is filtered by the membrane by application of centrifugal force to the membrane.
- Such membranes are often characterized by molecular weight (Mw) blocking, i.e., the maximum molecular size of a compound that can cross the membrane, beyond which compounds with a larger molecular size cannot cross the membrane.
- the storage stability means that the protein denaturation rate that may occur in the process of storing the purified human interferon-beta R27T mutant in a buffer or changing the composition of the buffer is lowered.
- the present invention relates to multiple sclerosis, cancer, autoimmune disorders, viral infections, HIV-related diseases, and hepatitis C for producing a formulation having a pharmacological effect of natural human interferon-beta.
- a human interferon-beta variant is provided.
- the 'effective amount' of the present invention means improvement, treatment, prevention, detection, and improvement of a disease selected from the group consisting of multiple sclerosis, cancer, autoimmune disorder, viral infection, HIV-related disease, hepatitis C when administered to an individual, refers to an amount exhibiting the effect of diagnosis or suppression or reduction of the disease, and the 'subject' may be an animal, preferably a mammal, particularly an animal including a human, and may be an animal-derived cell, tissue, organ, etc. . The subject may be a patient in need of the effect.
- 6a and 6b relate to ABN 101 (NT) and ABN 101 (CS) 50ml scale Fed-batch results.
- TORAY's HuIFN- ⁇ ELISA KIT is used to analyze it.
- the culture medium secured by Fed-batch is initially diluted 10,000-fold using diluent in the KIT, and serially dilution is performed two-fold to prepare up to 1,280,000-fold diluted samples.
- the ELISA plate is prepared by priming using the wash buffer in the KIT.
- Interferon-beta mutant (ABN 101(NT)) and interferon-beta double mutant (ABN 101(CS)) purified using Blue Sepharose resin were each purified using Reverse Phase High Performance Liquid Chromatography (RP-HPLC) 2 The content of the glycosylated form of interferon-beta mutant was measured.
- the recovery rate was confirmed by substituting the buffer with 20 mM sodium acetate (pH3.8) using a centricon in the same way to replace each protein exchanged with the corresponding buffer with a buffer based on a different formulation.
- the recovery rate of ABN 101 (CS) was also higher than that of ABN 101 (NT) when exchanged with an acetate-based buffer as shown in Table 7. This is interpreted as protein structural stability from physical factors such as centricon by increased stability by the double variant.
- the present invention provides a human interferon-beta mutant comprising an amino acid sequence in which the 27th amino acid, arginine, is substituted with threonine, and the 17th amino acid, cysteine, is substituted with serine.
- the present invention provides a human interferon-beta mutant with improved purification efficiency, which can be usefully used in the production of a therapeutic agent using the same, and thus has excellent industrial applicability.
Abstract
Description
Parameter | Condition |
Column | TMC Pack C4, 4x250 mm, 5 ㎛ |
Column Temperature | 25 ℃ |
Flow Rate | 1.0 mL/min |
Autosampler Temperature | 4 ℃ |
Wavelength | 214 nm or 280 nm |
Injection Volume | 50 ㎕ |
Time (min) | Eluent A (%) | Eluent B (%) |
0.0 | 70.0 | 30.0 |
1.0 | 70.0 | 30.0 |
18.0 | 45.0 | 55.0 |
18.1 | 0.0 | 100.0 |
22.0 | 0.0 | 100.0 |
22.1 | 70.0 | 30.0 |
30.3 | 70.0 | 30.0 |
Parameter | Condition |
Column | TSKgel G2000SKxL, 7.8mm x 300mm |
Column Temperature | 25 ℃ |
Flow Rate | 0.5 mL/min |
Autosampler Temperature | 4 ℃ |
Wavelength | 214 nm or 280 nm |
Injection Volume | Sample : 50 ㎕
GFS : 10 ㎕ |
Time (min) | Eluent A (%) | Eluent B (%) |
0.0 | 0.0 | 100.0 |
40.0 | 0.0 | 100.0 |
Material | 2 glycosylation | 1 glycosylation | MIU/mg |
ABN 101(NT) | 82.8 | 17.1 | 351 |
ABN 101(CS) | 93.1 | 6.9 | 360 |
Material | Initial Conc.
(mg/mL) |
20mM Na-Pi
(mg/mL) |
Recovery (%) |
ABN 101(NT) | 0.56 (30mL) | 1.1 (8mL) | 52 |
ABN 101(CS) | 0.40 (15mL) | 0.7 (8mL) | 93 |
Material | Initial Conc.
(mg/mL) |
20mM Na-OAc
(mg/mL) |
Recovery (%) |
ABN 101(NT) | 1.1 (1mL) | 0.86 (1mL) | 78 |
ABN 101(CS) | 1.7 (1.1mL) | 1.7 (1mL) | 91 |
Material | 20mM Na-Pi
(Monomer %) |
20mM Na-OAc
(Monomer %) |
Monomer
Recovery (%) |
ABN 101(NT) | 86.8% | 80.4% | 92.6 |
ABN 101(CS) | 98.1% | 90.2% | 91.8 |
ABN 101(NT) | HMWs (%) | Monomers (%) | LMWs (%) |
F/T 1cy | 5 | 76 | 19 |
F/T 3cy | 6 | 76 | 18 |
F/T 5cy | 5 | 77 | 18 |
ABN 101(CS) | HMWs (%) | Monomers (%) | LMWs (%) |
F/T 1cy | 8 | 89 | 3 |
F/T 3cy | 11 | 86 | 3 |
F/T 5cy | 13 | 84 | 3 |
ABN 101(NT)
(20mM Na-OAc) |
HMWs (%) | Monomers (%) | LMWs (%) |
Origin | 10 | 80 | < 10 |
F/T 3cy | 28 | 63 | < 9 |
ABN 101(CS)
(20mM Na-OAc) |
HMWs (%) | Monomers (%) | LMWs (%) |
Origin | 9 | 90 | < 1 |
F/T 3cy | 5 | 94 | < 1 |
Claims (21)
- 인간 인터페론-베타의 17번째 아미노산인 시스테인이 세린으로 치환되고 27번째 아미노산인 아르기닌이 트레오닌으로 치환된 아미노산 서열을 포함하는 인간 인터페론-베타 변이체.
- 제1항의 인간 인터페론-베타 변이체를 암호화하는 폴리뉴클레오티드.
- 제2항에 있어서,상기 인간 인터페론-베타 변이체는 서열번호 3의 아미노산 서열을 포함하는 인간 인터페론-베타 변이체인 것을 특징으로 하는 폴리뉴클레오티드.
- 제2항 기재의 폴리뉴클레오티드를 포함함으로써 동물 세포에서 인간 인터페론-베타를 발현시키는 발현 벡터.
- 제4항 기재의 발현 벡터로 형질 전환된 동물 세포.
- 제5항 기재의 동물 세포를 배양하는 단계를 포함하는 인간 인터페론-베타 변이체의 제조 방법.
- 제1항의 인간 인터페론-베타 변이체를 유효성분으로 함유하는 약제학적 조성물로서,상기 약제학적 조성물은 천연형 인간 인터페론-베타가 가지는 약리 효과를 가지는 것을 특징으로 하는 약제학적 조성물.
- 제7항에 있어서,상기 약제학적 조성물은 천연형 인간 인터페론-베타가 가지는 약리 효과를 가지고, 그 약리 효과는 다발성 경화증, 암, 자가 면역 장애, 바이러스 감염, HIV와 관련된 질병, C형 간염으로 구성된 군에서 선택되는 질병의 예방 또는 치료의 약리 효과인 것을 특징으로 하는 약제학적 조성물.
- 인간 인터페론-베타의 27번째 아미노산인 아르기닌이 트레오닌으로 치환된 인간 인터페론-베타 R27T 변이체의 17번째 아미노산인 시스테인을 세린으로 치환하는 단계를 포함하는, 인간 인터페론-베타 R27T 변이체의 안정성을 향상시키는 방법.
- 제9항에 있어서, 상기 인간 인터페론-베타 R27T 변이체는 서열번호 2의 아미노산 서열로 이루어진 것을 특징으로 하는 방법.
- 제9항에 있어서, 상기 안정성은 정제 안정성, 보관 안정성 및 냉동/해동 안정성으로 이루어진 군에서 선택되는 것을 특징으로 하는 방법.
- 제11항에 있어서, 상기 정제 안정성은 2당화(glycosylation) 단백질의 정제 효율 향상인 것을 특징으로 하는 방법.
- 제11항에 있어서, 상기 정제 안정성은 농축 및 완충액 교환시(buffer exchange) 단백질 응집현상(aggregation) 및 분해(degradation) 감소인 것을 특징으로 하는 방법.
- 제11항에 있어서, 상기 보관 안정성은 pH 2.0 내지 6.0의 완충액에서의 보관 안정성인 것을 특징으로 하는 방법.
- 제14항에 있어서, 상기 완충액은 아세트산, 인산, 암모니움 카보네이트, 암모니움 포스페이트, 붕산, 시트르산, 락트 산, 포타슘 시트레이트, 포타슘 메타포스페이트, 포타슘 포스페이트 일염기, 소듐 아세테이트, 소듐 시트레이트, 소듐 락테이트 용액, 이염기 소듐 포스페이트, 일염기 소듐 포스페이트, 비카보네이트, 트리스 (트리스(히드록시메틸)아미노메탄), MOPS (3-(N-모르폴리노)프로판술폰 산), HEPES (N-(2-히드록시에틸)피페라진-N'-(2-에탄술폰 산), ACES (2-(2-아미노-2-옥소에틸)아미노에탄술폰 산), ADA (N-(2-아세트아미도)2-이미노디아세트 산), AMPSO (3-(1,1-디메틸-1,2-히드록시에틸아미노-2-프로판술폰 산), BES (N,N-비스(2-히드록시에틸)-2-아미노에탄술폰 산, 비신 (N,N-비스(2-히드록시에틸글리신), 비스-트리스 (비스-(2-히드록시에틸)이미노-트리스(히드록시메틸)메탄, CAPS (3-(사이클로헥실아미노)-1-프로판술폰 산) , CAPSO (3-(사이클로헥실아미노)-2-히드록시-1-프로판술폰 산), CHES (2-(N-사이클로헥실아미노)에탄술폰 산), DIPSO (3-N,N-비스(2-히드록시에틸아미노-2-히드록시-프로판술폰 산), HEPPS (N-(2-히드록시에틸피페라진)-N'-(3-프로판술폰 산), HEPPSO (N-(2-히드록시에틸)피페라진-N'-(2-히드록시프로판술폰 산), MES (2-(N-모르폴리노)에탄술폰 산), 트리에탄올아민, 이미다졸, 글리신, 에탄올아민, 포스페이트, MOPSO (3-(N-모르폴리노)-2-히드록시프로판술폰 산), PIPES (피페라진-N,N'-비스(2-에탄술폰 산), POPSO (피페라진-N,N'-비스(2-히드록시프로판술폰 산), TAPS (N-트리스히드록시메틸)메틸-3-아미노프로판술폰 산), TAPSO (3-N-트리스(히드록시메틸)메틸아미노-2-히드록시-프로판술폰 산), TES (N-트리스(히드록시메틸)메틸-2-아미노에탄술폰 산), 트리신 (N-트리스(히드록시메틸)메틸글리신), 2-아미노-2-메틸-1,3-프로판디올, 및 2-아미노-2-메틸-1-프로판올로 이루어진 군에서 선택된 완충액인 것을 특징으로 하는 방법.
- 제11항에 있어서, 상기 냉동/해동 안정성은 -100℃내지 -10℃에서의 냉동 후 해동 안정성인 것을 특징으로 하는 방법.
- 제11항에 있어서, 상기 냉동/해동 안정성은 아세트산 완충액에서의 냉동/해동 안정성인 것을 특징으로 하는 방법.
- 제11항에 있어서, 상기 냉동/해동 안정성은 3회 이상의 냉동/해동 사이클 후 단백질의 응집현상(aggregation) 및 분해(degradation) 감소인 것을 특징으로 하는 방법.
- 다발성 경화증, 암, 자가 면역 장애, 바이러스 감염, HIV와 관련된 질병, C형 간염으로 구성된 군에서 선택되는 질병에 대한 천연형 인간 인터페론-베타가 가지는 약리 효과를 갖는 제제를 제조하기 위한 제1항의 인간 인터페론-베타 변이체의 용도.
- 천연형 인간 인터페론-베타가 가지는 약리 효과를 가지며, 제1항의 인간 인터페론-베타 변이체를 포함하는 조성물의 유효량을 이를 필요로 하는 개체에 투여하는 것을 포함하는 다발성 경화증, 암, 자가 면역 장애, 바이러스 감염, HIV와 관련된 질병, C형 간염으로 구성된 군에서 선택되는 질병 치료 방법.
- 서열번호 1의 인간 인터페론-베타의 17번째 아미노산인 시스테인이 세린으로 치환되고 27번째 아미노산인 아르기닌이 트레오닌으로 치환되고, 서열번호 1의 야생형 인터페론 베타와 90%이상의 서열 상동성을 가지며, 인터페론 베타의 활성을 가지는 인간 인터페론-베타 변이체.
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3177028A CA3177028A1 (en) | 2020-04-29 | 2021-04-29 | Human interferon-beta variant with double mutation and method for improving stability of human interferon-beta variant |
EP21796576.3A EP4144748A1 (en) | 2020-04-29 | 2021-04-29 | Human interferon-beta variant with double mutation and method for improving stability of human interferon-beta variant |
MX2022013662A MX2022013662A (es) | 2020-04-29 | 2021-04-29 | Variante del interferon-beta humano con doble mutacion y metodo para mejorar la estabilidad de la variante del interferon-beta humano. |
US17/921,339 US20230159605A1 (en) | 2020-04-29 | 2021-04-29 | Human interferon-beta variant with double mutation and method for improving stability of human interferon-beta variant |
BR112022022035A BR112022022035A2 (pt) | 2020-04-29 | 2021-04-29 | Interferon-beta humano variante, polinucleotídeo, vetor de expressão, célula animal transformada, métodos para preparar um interferon-beta humano variante, melhorar a estabilidade de um interferon-beta r27t humano variante e tratar uma doença, composição farmacêutica e uso |
AU2021264372A AU2021264372A1 (en) | 2020-04-29 | 2021-04-29 | Human interferon-beta variant with double mutation and method for improving stability of human interferon-beta variant |
CN202180046602.9A CN115989239A (zh) | 2020-04-29 | 2021-04-29 | 具有双重突变的人干扰素β变体和用于改善人干扰素β变体的稳定性的方法 |
JP2022566155A JP2023524248A (ja) | 2020-04-29 | 2021-04-29 | 二重突然変異を有するヒトインターフェロン-ベータ変異体及びヒトインターフェロン-ベータ変異体の安全性を向上させる方法 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2020-0052513 | 2020-04-29 | ||
KR10-2020-0052913 | 2020-04-29 | ||
KR20200052913 | 2020-04-29 | ||
KR20200052513 | 2020-04-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021221485A1 true WO2021221485A1 (ko) | 2021-11-04 |
Family
ID=78373740
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/005487 WO2021221485A1 (ko) | 2020-04-29 | 2021-04-29 | 이중 돌연변이를 가지는 인간 인터페론-베타 변이체 및 인간 인터페론-베타 변이체의 안정성을 향상시키는 방법 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20230159605A1 (ko) |
EP (1) | EP4144748A1 (ko) |
JP (1) | JP2023524248A (ko) |
KR (1) | KR102593710B1 (ko) |
CN (1) | CN115989239A (ko) |
AU (1) | AU2021264372A1 (ko) |
BR (1) | BR112022022035A2 (ko) |
CA (1) | CA3177028A1 (ko) |
MX (1) | MX2022013662A (ko) |
WO (1) | WO2021221485A1 (ko) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998028007A1 (en) * | 1996-12-24 | 1998-07-02 | Biogen, Inc. | Stable liquid interferon formulations |
KR100781666B1 (ko) | 2004-11-02 | 2007-12-03 | 신영기 | 인간 인터페론-베타 변이체 |
US20090208454A1 (en) * | 2007-05-02 | 2009-08-20 | Ambrx, Inc. | Modified interferon beta polypeptides and their uses |
US20120177603A1 (en) | 2009-07-07 | 2012-07-12 | Biogenerix Ag | Method for the purification of interferon-b |
KR20160013513A (ko) * | 2014-07-24 | 2016-02-04 | 에이비온 주식회사 | 페길화된 인터페론-베타 변이체 |
KR20180038290A (ko) * | 2016-10-06 | 2018-04-16 | 에이비온 주식회사 | 인터페론 베타 변이체의 안정화 제제 |
KR20200052513A (ko) | 2018-11-06 | 2020-05-15 | 삼성디스플레이 주식회사 | 유기 전계 발광 소자 및 유기 전계 발광 소자용 다환 화합물 |
KR20200052913A (ko) | 2017-09-12 | 2020-05-15 | 주식회사 다이셀 | 플라스틱 렌즈 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7670595B2 (en) * | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
-
2021
- 2021-04-29 KR KR1020210056013A patent/KR102593710B1/ko active IP Right Grant
- 2021-04-29 MX MX2022013662A patent/MX2022013662A/es unknown
- 2021-04-29 AU AU2021264372A patent/AU2021264372A1/en active Pending
- 2021-04-29 CA CA3177028A patent/CA3177028A1/en active Pending
- 2021-04-29 CN CN202180046602.9A patent/CN115989239A/zh active Pending
- 2021-04-29 US US17/921,339 patent/US20230159605A1/en active Pending
- 2021-04-29 WO PCT/KR2021/005487 patent/WO2021221485A1/ko unknown
- 2021-04-29 BR BR112022022035A patent/BR112022022035A2/pt unknown
- 2021-04-29 EP EP21796576.3A patent/EP4144748A1/en active Pending
- 2021-04-29 JP JP2022566155A patent/JP2023524248A/ja active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998028007A1 (en) * | 1996-12-24 | 1998-07-02 | Biogen, Inc. | Stable liquid interferon formulations |
KR100781666B1 (ko) | 2004-11-02 | 2007-12-03 | 신영기 | 인간 인터페론-베타 변이체 |
US20090208454A1 (en) * | 2007-05-02 | 2009-08-20 | Ambrx, Inc. | Modified interferon beta polypeptides and their uses |
US20120177603A1 (en) | 2009-07-07 | 2012-07-12 | Biogenerix Ag | Method for the purification of interferon-b |
KR20160013513A (ko) * | 2014-07-24 | 2016-02-04 | 에이비온 주식회사 | 페길화된 인터페론-베타 변이체 |
KR20180038290A (ko) * | 2016-10-06 | 2018-04-16 | 에이비온 주식회사 | 인터페론 베타 변이체의 안정화 제제 |
KR20200052913A (ko) | 2017-09-12 | 2020-05-15 | 주식회사 다이셀 | 플라스틱 렌즈 |
KR20200052513A (ko) | 2018-11-06 | 2020-05-15 | 삼성디스플레이 주식회사 | 유기 전계 발광 소자 및 유기 전계 발광 소자용 다환 화합물 |
Non-Patent Citations (1)
Title |
---|
ARDUINI, PROTEIN SCIENCE, vol. 8, 1999, pages 1867 - 1877 |
Also Published As
Publication number | Publication date |
---|---|
BR112022022035A2 (pt) | 2023-01-03 |
CN115989239A (zh) | 2023-04-18 |
KR102593710B1 (ko) | 2023-10-25 |
MX2022013662A (es) | 2023-02-01 |
CA3177028A1 (en) | 2021-11-04 |
JP2023524248A (ja) | 2023-06-09 |
KR20210133895A (ko) | 2021-11-08 |
EP4144748A1 (en) | 2023-03-08 |
US20230159605A1 (en) | 2023-05-25 |
AU2021264372A1 (en) | 2022-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2016346870B2 (en) | Dual function proteins and pharmaceutical composition comprising same | |
WO2010123290A2 (ko) | 체내 지속성을 유지함으로 체내 반감기가 증가된 단백질 또는 펩티드 융합체, 및 이를 이용하여 체내 반감기를 증가시키는 방법 | |
WO2014073842A1 (en) | Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment | |
WO2018056764A1 (ko) | 인슐린 수용체와의 결합력이 감소된, 인슐린 아날로그 및 이의 용도 | |
WO2019066586A1 (ko) | 글루카곤 유사 펩타이드-2(glp-2) 유도체의 지속형 결합체 | |
WO2018208011A2 (ko) | β-아밀로이드 단백질의 응집을 억제하는 생체친화적 펩타이드 | |
WO2021221485A1 (ko) | 이중 돌연변이를 가지는 인간 인터페론-베타 변이체 및 인간 인터페론-베타 변이체의 안정성을 향상시키는 방법 | |
WO2013039295A1 (ko) | 신규한 알파-1 안티트립신 변이체, 이의 제조방법 및 용도 | |
WO2022119380A1 (ko) | 신규한 ace2 변이체 및 그의 이용 | |
WO2012087017A2 (ko) | 변형된 인간 종양 괴사 인자 수용체-1 폴리펩티드 또는 그의 절편 및 그의 제조방법 | |
WO2022146036A1 (en) | Medium composition for culturing animal cells for producing recombinant extracellular matrix protein and method of using the same | |
WO2023027402A1 (ko) | 아프리카 돼지열병 바이러스 유래 항원 단백질을 포함하는 아프리카 돼지열병의 예방용 백신 | |
WO2022010319A1 (ko) | 글루카곤-유사 펩타이드-1 및 인터루킨-1 수용체 길항제를 포함하는 융합단백질 및 이의 용도 | |
WO2022015082A1 (ko) | 글루카곤 유도체 또는 이의 결합체의 간질환에 대한 치료적 용도 | |
WO2022080986A1 (ko) | Glp-1/gip 이중작용제, 이의 지속형 결합체, 및 이를 포함하는 약학적 조성물 | |
WO2021107519A1 (en) | Biotin moiety-conjugated polypeptide and pharmaceutical composition for oral administration comprising the same | |
WO2011049350A2 (ko) | 변형된 인간 종양 괴사 인자 수용체-1 폴리펩티드 또는 그의 절편 및 그의 제조방법 | |
WO2020138868A1 (ko) | 타입 1 인터페론 중화 fc-융합 단백질 및 이의 용도 | |
RU2812047C1 (ru) | Вариант интерферона-бета человека с двойной мутацией и способ улучшения стабильности варианта интерферона-бета человека | |
WO2021187904A1 (ko) | Il-2 단백질 및 cd80 단백질 단편 또는 이의 변이체를 포함하는 융합단백질 및 이의 용도 | |
AU2019404719B2 (en) | Fusion protein comprising human lefty a protein variants and use thereof | |
WO2024035137A1 (ko) | 바실러스 서브틸리스 플라젤린 변이체 및 이의 용도 | |
WO2023132609A1 (ko) | 지속형 지방산-펩타이드 유도체 및 이의 용도 | |
WO2022080991A1 (ko) | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 호흡기 감염 질환의 후유증의 치료 용도 | |
WO2023059160A1 (ko) | 섬유증의 예방 또는 치료용 융합 단백질 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21796576 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3177028 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2022566155 Country of ref document: JP Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022022035 Country of ref document: BR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021796576 Country of ref document: EP Effective date: 20221129 |
|
ENP | Entry into the national phase |
Ref document number: 2021264372 Country of ref document: AU Date of ref document: 20210429 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112022022035 Country of ref document: BR Kind code of ref document: A2 Effective date: 20221028 |